Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.

Abstract

and conclusions An alpha-glucosidehydrolase inhibitor (acarbose; BAY g 5421) taken with food was compared with dummy tablets in seven insulin-treated diabetic patients over eight-hour periods that included breakfast, lunch, and two snacks. Acarbose diminished the postprandial increases in blood glucose, lactate, and pyruvate concentrations and may therefore be of value in the management of insulindependent diabetes.

Improvement of metabolic control in insulin dependent diabetics treated with the ?-glucosidase inhibitor Acarbose for two months

“…Until now, the potential benefit of Acarbose in insulin treated diabetics has been investigated in two short-term studies only. Walton et al [6] reported a double-blind study in seven diabetics receiving Acarbose or placebo on two days at weekly intervals. They observed that Acarbose diminished the post-prandial increases in blood glucose, lactate and pyruvate concentrations.…”

“…Short-term metabolic studies have suggested that Acarbose may be a useful additional treatment for diabetic patients [5][6][7].The aim of the present study was to investigate the potential benefits of Acarbose in insulin dependent diabetics over a period of two months. The experiment was conducted with a single-blind protocol in which the patients were given a placebo for two months before and two months after the treatment period.…”

Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients.

“…-glucoside-hydrolase in hibitor; serum lipoproteins; fecal flora; bile acids; meteorism A new glucoside-hydrolase inhibitor (Bay g 5421, Bayer AG, West Germany), when taken orally, is known to delay the intestinal absorption of starch and sucrose by inhibiting maltase and sucrase activities (Schmidt et al 1977;Puls et al 1977). Since this acarbose diminishes the postprandial increase of blood glucose, it may be of value in the management of diabetic patients (Walton et al 1979;Sachse and Willms 1979). Our previous study also revealed that the administration of the drug.…”

Effect of a long-term acarbose therapy on the metabolic control of sulphonylurea-treated diabetic patients

“…It has been reported that aprotinin increases the rate and absolute amount of insulin absorption from the subcutaneous tissue of non-diabetics [10] and reduces the subcutaneous insulin requirements in some insulin-resistant diabetics [9, 1 l, 12], while others have been unable to confirm these findings in a Type 1 (insulin-dependent) diabetic patient [8] or in Type 2 (non-insulin dependent) diabetic subjects [1]. However, the latter group did not report glycaemic changes and concluded that aprotinin had no el-…”

“…Dear Sir, I would like to add some cautionary comments regarding the confusion over the extent of insulin degradation at the subcutaneous injection site in experimental animals and man reported in this journal [1] and elsewhere.…”